The newly identified LINC01419/YBX1‐PDK1 axis constitutes a valuable target, and hepatic‐specific delivery of GalNAc‐siLINC01419 presents a potential therapeutic approach for HCC. The gene discussed is PDK1; the disease is hepatocellular carcinoma.